Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 7:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Thrombophilia Clear all
Completed No phase listed Observational

Study of Abnormal Blood Clotting in Children With Stroke

NCT00001927
View directory record Official record
Conditions
Abnormalities, Blood Coagulation Disorder, Brain Disease, Cerebrovascular Accident, Vascular Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Up to 45 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 31, 2026, 7:41 PM EDT
Terminated Phase 2 Interventional Results available

Antithrombin III in Infectious Disease Caused by COVID-19

NCT04899232
View directory record Official record
Conditions
Antithrombin III Deficiency, Covid19
Interventions
Antithrombin III
Drug
Lead sponsor
Enrique Ginzburg
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 31, 2026, 7:41 PM EDT
Completed No phase listed Observational

Coagulation Changes Associated With COVID-19 Infection

NCT04460664
View directory record Official record
Conditions
COVID, Disseminated Intravascular Coagulation, Coagulation Disorder
Interventions
Quantra System
Diagnostic Test
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 31, 2026, 7:41 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)

NCT01054443
View directory record Official record
Conditions
Immune Thrombocytopenia (ITP)
Interventions
Placebo, Lusutrombopag
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
19
States / cities
Anaheim, California • Los Angeles, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 31, 2026, 7:41 PM EDT
Completed No phase listed Observational

Safety Monitoring of Patients Having Pulmonary Vein Ablation

NCT00590668
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Transesophageal Echocardiography
Diagnostic Test
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 31, 2026, 7:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating the Relationship Between Blood Clotting Disorders, Inflammation, and Obesity in Individuals With Venous Disorders and Post-Thrombotic Syndrome

NCT00395265
View directory record Official record
Conditions
Venous Thrombosis, Venous Insufficiency
Interventions
Not listed
Lead sponsor
University of Vermont
Other
Eligibility
40 Years to 79 Years
Enrollment
2,211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Oct 31, 2026, 7:41 PM EDT
Completed Phase 3 Interventional

TIPPS: Thrombophilia in Pregnancy Prophylaxis Study

NCT00967382
View directory record Official record
Conditions
Pregnancy, Thrombophilia, Pregnancy Complications
Interventions
dalteparin sodium
Drug
Lead sponsor
Ottawa Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
2
States / cities
St Louis, Missouri • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 31, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)

NCT02878603
View directory record Official record
Conditions
Acquired Thrombotic Thrombocytopenic Purpura
Interventions
Caplacizumab, Standard of Care
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
St Louis, Missouri • Valhalla, New York • Durham, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 31, 2026, 7:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Guilford Genomic Medicine Initiative (GGMI)

NCT01372553
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Colon Cancer, Thrombophilia
Interventions
Not listed
Lead sponsor
The Moses H. Cone Memorial Hospital
Other
Eligibility
18 Years and older
Enrollment
1,184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Oct 31, 2026, 7:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 31, 2026, 7:41 PM EDT
Terminated Phase 2 Interventional Results available

Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)

NCT00953771
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Danazol
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 31, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Results available

Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

NCT03922308
View directory record Official record
Conditions
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Interventions
Placebo, SHP655, Standard of Care
Other · Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Birmingham, Alabama • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 31, 2026, 7:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Thromboelastography to Assess Age-Related Coagulation Differences in Patients Undergoing Cesarean Delivery

NCT01416454
View directory record Official record
Conditions
Thrombophilia
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2013 · Synced Oct 31, 2026, 7:41 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

NCT04683003
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
TAK-755
Biological
Lead sponsor
Takeda
Industry
Eligibility
0 Years to 70 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Buffalo, New York • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 31, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

NCT02553317
View directory record Official record
Conditions
Acquired Thrombotic Thrombocytopenic Purpura
Interventions
Caplacizumab, Placebo
Biological
Lead sponsor
Ablynx, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 31, 2026, 7:41 PM EDT
Terminated No phase listed Observational

Octaplas Adult TTP Trial

NCT01938404
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Octaplas, Standard Plasma
Biological · Drug
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Manhasset, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 31, 2026, 7:41 PM EDT
Recruiting No phase listed Observational

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

NCT04398628
View directory record Official record
Conditions
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
Interventions
Not listed
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2035
U.S. locations
76
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 60 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 31, 2026, 7:41 PM EDT
Terminated No phase listed Observational

Thrombin Generation and Thromboelastography in Non-overt DIC

NCT00299949
View directory record Official record
Conditions
Sepsis, Disseminated Intravascular Coagulation
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 31, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Results available

Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura

NCT01554514
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
rituximab
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
4
States / cities
Atlanta, Georgia • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 31, 2026, 7:41 PM EDT
Recruiting No phase listed Observational

Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)

NCT01257269
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura, Congenital Thrombotic Thrombocytopenic Purpura, Familial Thrombotic Thrombocytopenic Purpura, Thrombotic Thrombocytopenic Purpura, Congenital, Upshaw-Schulman Syndrome
Interventions
Observation
Other
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Other
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2030
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 31, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

NCT03393975
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
TAK-755, Standard of care
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
0 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
7
States / cities
Atlanta, Georgia • Las Vegas, Nevada • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 31, 2026, 7:41 PM EDT
Completed No phase listed Observational

Determination of Performance Characteristics of the MassPLEX Factor II/V Leiden Test

NCT01835483
View directory record Official record
Conditions
Factor V Leiden, Factor II, Thrombosis
Interventions
Not listed
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
867 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Grand Rapids, Michigan • Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2014 · Synced Oct 31, 2026, 7:41 PM EDT
Completed No phase listed Observational

Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)

NCT01475149
View directory record Official record
Conditions
Antiphospholipid Syndrome, Thrombophilia Due to Antiphospholipid Antibody, Systemic Lupus Erythematosus
Interventions
Phlebotomy
Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 31, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

NCT05468320
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Caplacizumab, Corticosteroids, anti-CD20 antibody
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Baltimore, Maryland • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 31, 2026, 7:41 PM EDT